Few domains of philanthropy have been transformed more thoroughly by the evidence revolution than global health. The combination of randomized controlled trials borrowed from clinical medicine, cost-effectiveness analysis adapted from economics, and the intellectual force of the effective altruism movement has reshaped the questions that serious donors ask—and the answers that serious organizations provide. The result is a field that is simultaneously more rigorous, more controversial, and more productive than it was twenty years ago.
The GiveWell Methodology: Cost-Per-Life as Analytical Anchor
GiveWell was founded in 2007 by two former hedge fund analysts who were dissatisfied with the quality of information available to donors seeking to maximize their philanthropic impact. The founders—Holden Karnofsky and Elie Hassenfeld—applied financial analysis methodology to nonprofit evaluation, asking not whether organizations were well-managed or mission-aligned, but whether their interventions produced measurable improvements in human welfare per dollar deployed.
The core metric that GiveWell developed is cost per life saved—the estimated cost, in dollars, of averting one death through a specific intervention. While the metric sounds clinical to the point of callousness, it encodes a genuinely important ethical commitment: that a donor who cares about human welfare should direct resources to interventions where each dollar saves the most lives, rather than to causes that are merely compelling.
GiveWell’s methodology involves several layers of analysis. First, identifying interventions with strong evidence of effectiveness—typically, randomized controlled trials that demonstrate the intervention produces the claimed health outcome under realistic field conditions. Second, estimating the cost of delivery for that intervention in the specific context where the grantee operates. Third, extrapolating from the evidence to estimate the additional lives saved by additional funding—the “room for more funding” analysis that distinguishes an organization that can productively deploy additional capital from one that has reached the limits of its absorptive capacity.
The resulting recommendations have consistently converged on a small number of high-impact global health interventions: distribution of insecticide-treated bed nets to prevent malaria, vitamin A supplementation for young children, treatment of severe acute malnutrition, and cash transfers to extremely poor households. These interventions share a common profile—strong evidence of effectiveness from multiple high-quality studies, low cost of delivery relative to the magnitude of health impact, and significant funding gaps that philanthropy can address.
GiveWell’s top recommended organization, the Against Malaria Foundation, has distributed more than 260 million bed nets since its founding, with independent evaluations suggesting a cost per death averted of approximately $3,000 to $5,000. At this cost-effectiveness level, a gift of $10,000 to $15,000 saves a life—a standard of impact that dwarfs what comparable gifts to most developed-world charitable causes could achieve.
GiveDirectly: The Cash Transfer Challenge
GiveDirectly represents the most direct challenge to conventional development philanthropy: what if, instead of funding programs designed by outside experts, donors simply gave cash directly to extremely poor households and trusted those households to allocate it most effectively?
The organization, founded in 2008, provides unconditional cash transfers to households living below $1.90 per day in Kenya, Uganda, Rwanda, and Malawi. Recipients decide how to spend the money. GiveDirectly tracks outcomes through rigorous follow-up surveys and has partnered with academic economists to conduct randomized controlled trials of its interventions.
The evidence from these studies is striking. Cash transfer recipients spend most of the money on food, housing improvements, and productive investments—not the tobacco, alcohol, and “temptation goods” that skeptics predicted. Asset ownership increases. Mental health improves. Children’s school attendance rises. Long-term follow-up studies suggest impacts that persist for years after the transfers are completed.
The GiveDirectly model also serves as a benchmark against which other development interventions can be evaluated. If a program cannot demonstrate outcomes that a comparable cash transfer would not produce at similar cost, that is a meaningful challenge to its value proposition. This “cash benchmark” test has sharpened thinking across the development sector about what interventions add value beyond simply providing resources.
The limitations of the cash transfer model are real but often overstated. Unrestricted cash does not build the physical infrastructure—roads, schools, health clinics—that sustained development requires. It does not create the institutions, policies, and systems that generate sustained economic growth. And its efficacy may depend on local market conditions—the ability to buy goods and services that improve welfare—that are not universal. Cash transfers are a powerful tool for reducing acute deprivation; they are not a theory of development.
Advance Market Commitments: Market-Making Philanthropy
The advance market commitment (AMC) represents one of the most innovative instruments in global health philanthropy: a contractual commitment by donors to subsidize the purchase of a vaccine not yet fully developed, at a guaranteed price, if an eligible vaccine is brought to market.
The logic is elegant. Vaccine manufacturers have little financial incentive to develop vaccines for diseases that primarily affect low-income populations, because those populations cannot pay prices that cover development and manufacturing costs. AMCs address this failure by guaranteeing a market at commercially viable prices, funded by donor capital, for vaccines that meet specified efficacy and safety criteria.
The first AMC, covering pneumococcal vaccines that prevent bacterial pneumonia and meningitis, launched in 2009 with $1.5 billion in commitments from the Gates Foundation, the United Kingdom, Canada, Russia, Italy, and Norway, administered through the Global Alliance for Vaccines and Immunizations (GAVI). The program has since supported the immunization of hundreds of millions of children. Subsequent analyses suggest it accelerated pneumococcal vaccine availability in low-income countries by approximately a decade relative to what would have happened under normal market dynamics.
The COVID-19 experience raised the profile of AMC-style instruments significantly. COVAX, the international effort to ensure equitable COVID-19 vaccine access, was structured partly as an AMC and partly as a pooled procurement mechanism. Its successes and failures have generated substantial learning about the conditions under which advance market commitments work and where the model needs refinement.
Evaluating Global Health Organizations
For donors without the capacity to conduct GiveWell-style analysis independently, the evaluation challenge is largely one of identifying and trusting credible intermediaries. GiveWell’s top recommendations represent one such list; the Giving What We Can pledge organization maintains another; Open Philanthropy, the foundation associated with Dustin Moskovitz and Cari Tuna, conducts its own analysis and publishes findings that serve as a useful complement.
Beyond intermediary recommendations, several dimensions of organizational quality are worth probing directly. Does the organization have a clearly articulated theory of change that specifies the causal mechanism linking its activities to health outcomes? Does it conduct rigorous monitoring of program implementation and report results honestly, including failures? Does it subject its programs to external evaluation by independent researchers? Does its financial management pass basic tests of accountability—clean audit opinions, reasonable overhead ratios, transparent financial reporting?
The global health field has developed specialized intermediary structures that give donors access to portfolio-level expertise. The Global Fund to Fight AIDS, Tuberculosis and Malaria aggregates donor contributions and deploys them according to evidence-based protocols, providing individual donors with effective access to diversified global health investment. GAVI, the vaccine alliance, channels philanthropic contributions alongside government funding into vaccination programs across low-income countries.
The Tension Between Impact and Narrative
Global health philanthropy operates in persistent tension between impact and narrative. The interventions that GiveWell identifies as most cost-effective—bed nets, vitamin A supplements, cash transfers—do not make for compelling fundraising stories. They lack the drama of surgical missions, the visibility of clean water projects, or the emotional resonance of sponsor-a-child campaigns.
This tension is not merely aesthetic. It shapes the philanthropic market in ways that direct significant resources away from high-impact interventions toward programs with more compelling stories but weaker evidence. Donors who want to maximize impact must consciously resist narrative appeal and maintain focus on the evidence.
The effective altruism movement, for all the controversies that have attached to it in recent years, has made a genuine intellectual contribution by articulating this tension explicitly and providing frameworks for navigating it. The core insight—that doing the most good requires thinking rigorously about what actually works, not just what feels virtuous—is correct and important. The challenge is applying it with the humility that acknowledges evidence is incomplete, moral philosophy is contested, and the conditions under which interventions succeed are specific and sometimes fragile. The donors who do this most thoughtfully are among the most effective in any domain of philanthropy.
[ QUICK POLL // 60 SECONDS ]